CA-PROLIFIC-MACHINES
Prolific Machines, a next generation biotechnology company, is emerging from stealth today by announcing their massively oversubscribed Seed and Series A financings, led by the best VCs in the space. The Seed round was led by Arvind Gupta at Mayfield, the first investor in cultured meat. The Series A was led by Bill Gates-founded Breakthrough Energy Ventures. Prolific’s first check was written in late 2020, when SOSV’s IndieBio led their Pre-Seed round.
The lead VCs were joined by a number of high profile co-investors such as David Adelman, Mark Cuban (owner of the Dallas Mavericks), The Kraft Group (owners of the New England Patriots), David Rubenstein, Michael Rubin, Breyer Capital, The SALT Fund, Purple Orange Ventures, Fred Blackford, Jake Poliskin, and Baruch Future Ventures. A number of celebrities and restaurateurs have also invested in Prolific including: Kevin Love, Tobias Harris, Meek Mill, Ciara & Russell Wilson, Emily Ratajkowski, Maverick Carter, Sean Feeney, Michael Schulson, Mark Bucher, and RJ Melman.
Prolific is unique in that they are inventing the scalable manufacturing process first, and a product second. This is very different to the path taken by other cultured meat companies. Prolific aims to do for biology what Henry Ford did for automobiles. In 1906, there were hundreds of car companies, yet most people could not afford a car. After Ford invented the assembly line for automobiles, car production became scalable, and then cars became a mass market item. Prolific is inventing the technology that holds the key to building a scalable assembly line for biology.
Dr. Deniz Kent, Co-founder and CEO of Prolific Machines, started the company after witnessing the Syrian refugee crisis in his hometown of Antioch, Turkey. He realized that what he experienced would be nothing compared to the impending global refugee crises caused by climate change. He knew his expertise in stem cell biology could be used to create a sustainable food system, but lacked confidence in the ability of existing technologies to compete with factory farming on cost. He conceived of a new way to grow and control cells without the need for any recombinant proteins, the most expensive ingredients in cell production. He spent three years searching for the perfect co-founders while the idea marinated in his mind. He eventually found a brilliant physicist Dr. Max Huisman, and an exceptional machine learning engineer Declan Jones. Deniz convinced them to quit their jobs, and together they assembled an all-star team to embark upon a journey to revolutionize biomanufacturing.
“We are of the opinion that existing technologies being deployed in cultured meat will not reach price parity with factory farming. A fundamentally new approach is going to be required. We are inventing this new approach, and I'm open to making our technology available to every meat company. Our mission is to address the existential risks posed by our changing climate, and we have no time to waste,” said Deniz.
Arvind Gupta, partner at Mayfield and first investor in many prominent food companies, says of the Seed round, “I never intended to invest in another cultured meat company. But when Deniz showed me what they were doing, I was blown away by the creativity in their approach to reinvent the assembly line for food production. It is my goal to help reverse climate change by partnering with incredible teams, and I am convinced Prolific Machines will be a winner in the race for sustainable food production.”
After making quick progress, Breakthrough Energy Ventures met the team and was similarly impressed. “Prior to meeting Prolific we had come to the conclusion that a fundamental breakthrough would be required for cultured meat to be economically competitive with conventional meat production,” said Carmichael Roberts, Breakthrough Energy Ventures. “We believe that Prolific Machines may be this breakthrough. Prolific’s novel technology has the potential to enable the cost-competitive production of high-quality cultured meat products and they have the team to execute it."
Po Bronson, Managing Director at IndieBio and General Partner at SOSV, was the first to recognise Prolific’s potential. He wrote the Pre-Seed check, and incubated them from IndieBio while they de-risked their early science. “Prolific was a radical idea with a truly incredible team, exactly what IndieBio loves. Prolific has broken all of the records at IndieBio, and I see their technology as the best in this space.”
Deniz explains the next steps. “We are building a 25,000 square foot HQ in Emeryville and ramping up hiring to expand our assembly line programs, including fish, poultry, and beef. If you are talented and looking to make a historic change, come and talk to us.”
If you would like to support us, you can join the waitlist and find out more information at www.prolific-machines.com.
About Prolific Machines
Prolific Machines is a biomanufacturing company inventing novel technologies to grow and differentiate stem cells at a dramatically lower cost relative to conventional means. The initial focus of the company is cultured meat, but the technology they are developing is cell-agnostic, meaning that it could be applied to myriad of different applications in biotechnology. Further information is available at www.prolific-machines.com, and you can stay updated by following the company on LinkedIn.
About Breakthrough Energy Ventures
Founded by Bill Gates and backed by many of the world’s top business leaders, BEV has raised more than $2 billion in committed capital to support cutting-edge companies that are leading the world to net-zero emissions. BEV is a purpose-built investment firm that is seeking to invest, launch and scale global companies that will eliminate GHG emissions throughout the economy as soon as possible. BEV seeks true breakthroughs and is committed to supporting these entrepreneurs and companies by bringing to bear a unique combination of technical, operational, market and policy expertise.
BEV is a part of Breakthrough Energy, a network of investment vehicles, philanthropic programs, policy advocacy, and other activities committed to scaling the technologies we need to reach net-zero emissions by 2050. Visit www.breakthroughenergy.org to learn more.
About Mayfield
Mayfield is a global venture capital firm with a people-first philosophy and a 50+ year track record of inception and early-stage investing, partnering with founders to build iconic enterprise, consumer and engineering biology companies. Since its founding, the firm has invested in more than 500 companies, resulting in 120 IPOs and more than 200 acquisitions, and currently has $2.2B under management. For more information, go to https://www.mayfield.com or follow @MayfieldFund.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release
Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release
Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 07:00:00 CEST | Press release
Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilienceMerck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricityNew Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028 Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom